A news article about a newly listed chemotherapy-free immunotherapy combination for relapsed or refractory follicular lymphoma, highlighting regulatory and reimbursement developments and what readers can expect to learn about the therapy’s role in treatment options.
Key Takeaways
- PBS listed a CD19 and CD20 dual-targeted immunotherapy combined with lenalidomide for R/R follicular lymphoma
- In the Phase 3 inMIND trial the combination reduced risk of progression or death by 57% versus control
- Common adverse reactions included infections, neutropenia, rash, asthenia, and infusion related reactions